An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006844
Abstract: Key Points Bendamustine with rituximab is a highly effective frontline therapy in extranodal marginal zone lymphoma across all extranodal sites. Bendamustine with rituximab overcomes known poor prognosis features in extranodal marginal zone lymphoma. read more here.
Keywords: international analysis; bendamustine rituximab; extranodal marginal; marginal zone ... See more keywords